N-acetylcysteine for Attenuation of COVID Symptomatology
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Symptom severity
研究概览
简要总结
The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.
详细描述
STUDY DESIGN: Randomized double-blinded placebo-controlled trial
ELIGIBILITY
Inclusion criteria:
- age 18 years and older
- participants will need daily access to use of a smartphone for at least six weeks from time of enrollment
- Positive COVID-19 test within 10 days of date of enrollment
- not already hospitalized for treatment of COVID
Exclusion criteria:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Participants and study team members will be masked to whether a participant is receiving the study drug or placebo
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •positive COVID test <= 7 days of enrollment
排除标准
- •already hospitalized due to COVID
研究组 & 干预措施
NAC
Group receiving intervention/study drug NAC
干预措施: N-acetylcysteine (Drug)
Placebo
Group receiving placebo
干预措施: Placebo (Other)
结局指标
主要结局
Symptom severity
时间窗: 24 weeks starting the day after enrollment
Severity of symptoms
Symptom duration
时间窗: 24 weeks starting the day after enrollment
Length in days of symptoms
次要结局
- Need for higher level of care/hospitalization(24 weeks starting the day after enrollment)
研究者
Melisa Lai-Becker
Chief, CHA Everett Emergency Department; Director, CHA Division of Medical Toxicology
Cambridge Health Alliance